Day One Biopharmaceuticals (DAWN) Equity Average: 2022-2025
Historic Equity Average for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $455.9 million.
- Day One Biopharmaceuticals' Equity Average rose 5.74% to $455.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.9 million, marking a year-over-year increase of 5.74%. This contributed to the annual value of $424.6 million for FY2024, which is 25.16% up from last year.
- According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Equity Average is $455.9 million, which was down 3.05% from $470.2 million recorded in Q2 2025.
- Day One Biopharmaceuticals' Equity Average's 5-year high stood at $529.1 million during Q4 2024, with a 5-year trough of $301.8 million in Q2 2024.
- Over the past 3 years, Day One Biopharmaceuticals' median Equity Average value was $407.8 million (recorded in 2023), while the average stood at $405.1 million.
- Its Equity Average has fluctuated over the past 5 years, first decreased by 16.92% in 2024, then surged by 55.81% in 2025.
- Over the past 4 years, Day One Biopharmaceuticals' Equity Average (Quarterly) stood at $347.6 million in 2022, then increased by 5.91% to $368.1 million in 2023, then surged by 43.75% to $529.1 million in 2024, then increased by 5.74% to $455.9 million in 2025.
- Its last three reported values are $455.9 million in Q3 2025, $470.2 million for Q2 2025, and $491.1 million during Q1 2025.